The board (the "Board") of directors (the "Directors") of China Tian Yuan Healthcare Group Limited (the "Company", together with its subsidiaries, the "Group") announced that the Board has approved the resignation of Mr. Wang Huabing ("Mr. Wang ") as the executive Director, the chairman of the Board (the " Chairman"), the member of the nomination committee of the Board (the " Nomination Committee ") and an authorized representative (an " Authorized Representative") of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited with effect from 4 November 2022 due to his personal commitments. Mr. Wang has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited and the shareholders of the Company. The Board announced that Ms. Dong Wei ("Ms. Dong"), the chief executive officer and executive Director of the Company, has been appointed as Acting Chairman and Member of Nomination Committee of the Company with effect from 4 November 2022.

The Board will proceed to make succession arrangements in due course. Ms. Dong, aged 28, obtained a bachelor degree in Marketing from Anglia Ruskin University, United Kingdom in 2016. Ms. Dong joined the Group in July 2021 and was appointed as the executive Director of the Company on 30 December 2021.

Before her appointment as the executive Director of the Company, she has been serving as the director assistant of the Company, during which she has been responsible for assisting the directors with planning and implementing strategies. Ms. Dong served as assistant manager of human resources department of China Huarong Asset Management Co. Ltd., (Stock Code: 02799HK) from June 2017 to February 2019.

From February 2019 to July 2021, Ms. Dong served as administrative manager of international trade department in Beijing Tianyuan Manganese Industry Co. Ltd. Ms. Dong is a daughter of Mr. Jia Tianjiang (being the controlling shareholder of the Company). Save as disclosed above, Ms. Dong does not hold any other position within the Group; has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company.

As at the date of this announcement, so far as the Directors are aware of, Ms. Dong is not interested or deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO"). Ms. Dong has entered into a service contract with the Company under which she agreed to act as an executive Director of the Company for a term of two years commencing from 30 December 2021. Ms. Dong shall hold office of the executive Director until the next following general meeting of the Company at which she shall be eligible for re-election in accordance with the articles of association of the Company (the "Articles").

Such appointment is also subject to retirement by rotation at least once every three years in accordance with the Articles. Ms. Dong and the Company will not enter into a new service contract for her appointment as the Acting Chairman and the member of the Nomination Committee. Ms. Dong is entitled to a fixed sum salary of RMB 600,000 per annum and a discretionary bonus as may be approved by the Board.

Her emoluments were recommended by the Remuneration Committee and determined by the Board with reference to, among others, her duties and responsibilities with the Company, her experience and the prevailing market conditions. No additional remuneration will be paid to Ms. Dong for her appointment as the Acting Chairman and the member of the Nomination Committee.